Patrick O’Donnell Now GM, EVP at BONESUPPORT

Patrick O’Donnell, a veteran of three CEO roles, has now joined BONESUPPORT AB as General Manager and Executive Vice President, North American Commercialization. O’Donnell will work with Zimmer Biomet to enhance the revenue related to BONESUPPORT’s CERAMENT BONE VOID FILLER (BVF).

The November 7, 2016 news release states, “O’Donnell joins BONESUPPORT after serving as CEO of three companies focused on innovative orthopaedic regenerative technologies. Following his role as CEO of Histogenics Corporation, he was most recently the Co-Founder and CEO of ProteoThera Inc., based in Cambridge, MA. His experience includes being head of Global Marketing of Confluent Surgical, where he launched and built the DuraSeal brand of surgical dural sealant products, currently owned by Integra LifeSciences In addition, he spent 13 years in sales, sales management and marketing in orthobiologics and medical devices at Johnson & Johnson’s DePuy Spine Division.”

BONESUPPORT CEO Richard Daviesof said, “We are excited to welcome Patrick to the BONESUPPORT team, particularly after completing the recent financing, which will be crucial to executing our strategy. Patrick brings with him a great breadth of experience ranging from start-ups to small and large companies. He has an in-depth of knowledge of the orthobiologics space and appreciation of the significant potential of our unique CERAMENT drug eluting osteoconductive bioceramic platform to develop a pipeline of novel products for a broad range of bone diseases. The clinical value proposition of our products is expected to become increasingly relevant to the U.S. healthcare market which is undergoing a sea change to value based care.”

O’Donnell told OTW, “I have been excited by the opportunity that BONESUPPORT has to further develop its fast growing business in North America given the multiple attractions of its CERAMENT based products. I believe CERAMENT BVF, which is marketed in the U.S. by our partner Zimmer Biomet, has the potential to generate a much higher level of sales. This is based on its ability to be injected percutaneously, completely and safely fill bone voids and to remodel to host bone in 6 to 12 months, properties which are attractive to both surgeons and payers. I am also looking forward in time to the anticipated launch of CERAMENT G which could offer a major improvement in the management of patients with or at a high risk of developing bone infections.”

“I believe that some of my collective experiences in the orthobiologics space from my roles in sales, sales management and marketing at Johnson & Johnson’s DePuy Spine Division as well as Confluent Surgical, Inc. has prepared me ideally for my new position at BONESUPPORT. I also expect to benefit from my sharpened entrepreneurial instincts as a result of my more recent experience at a few late clinical stage start up tissue regeneration businesses.”